Valuation: Cadrenal Therapeutics, Inc.

Market Cap 3.85M 3.43M 3.2M 2.92M 5.48M 371M 5.56M 38.63M 14.98M 189M 14.47M 14.15M 609M P/E 2026 *
-0.25x
P/E 2027 * -0.32x
Enterprise Value 3.85M 3.43M 3.2M 2.92M 5.48M 371M 5.56M 38.63M 14.98M 189M 14.47M 14.15M 609M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.07%
Yield 2026 *
-
Yield 2027 * -
08-31 Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of Cad-1005 in Heparin-Induced Thrombocytopenia CI
08-13 Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Cadrenal Therapeutics Solidifies Multi-Indication Strategy For CAD-1005 In Cardiac Acute Critical Care CI
07-13 Cadrenal Therapeutics, Inc. Demonstrates Greater Than 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Hit Clinical Trial CI
07-10 Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 CI
07-01 Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million MT
06-29 Cadrenal Therapeutics, Inc. announced that it expects to receive $3 million in funding CI
06-29 Cadrenal Therapeutics, Inc. Announces CFO Changes CI
06-29 Cadrenal Therapeutics, Inc. Announces Board and Committee Changes CI
06-24 Cadrenal Therapeutics Announces Selection of Cad-1005 Phase 2 Study for Late-Breaking Oral Presentation At Isth Congress CI
06-18 Cadrenal Therapeutics, Inc. Plans To Submit Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease CI
06-18 Cadrenal Therapeutics to Seek US FDA's Rare Pediatric Disease Designation for Tecarfarin to Treat Children With Kawasaki Disease MT
06-15 Cadrenal Therapeutics Advances Multi-Indication Strategy For CAD-1005 And Launches Phase 2a Acute Kidney Injury Clinical Plan CI
1 day-10.19%
1 week-26.52%
Current month-10.19%
1 month-44.57%
3 months-70.96%
6 months-81.05%
Current year-85.69%
1 week 0.97
Extreme 0.97
1.25
1 month 0.97
Extreme 0.97
1.53
Current year 0.97
Extreme 0.97
8.96
1 year 0.97
Extreme 0.97
14.64
3 years 0.97
Extreme 0.97
32.55
5 years 0.97
Extreme 0.97
101.25
10 years 0.97
Extreme 0.97
101.25
Manager TitleAgeSince
Chief Executive Officer 61 24/01/2022
Director of Finance/CFO 61 24/06/2026
Chief Operating Officer 58 05/02/2024
Director TitleAgeSince
Director/Board Member 76 18/01/2023
Director/Board Member 78 18/01/2023
Chairman 61 24/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
02/06/26 Sell

Chief Executive Officer

-349 0.0122%
28/05/26 Sell

Chief Executive Officer

-2,989 0.1192%
22/05/26 Sell

Chief Executive Officer

-1,165 0.0465%
Change 5-day change 1-year change 3-year change Capi.($)
-10.19%-26.52%-92.99%-90.49% 3.85M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -1.06%-0.05%+40.59%+129.80% 39.68B
Weighted average by Cap. +0.17%+1.83%+60.06%+145.78%

Financials

2026 *2027 *
Net sales - -
Net income -12.6M -11.21M -10.46M -9.55M -17.91M -1.21B -18.18M -126M -49M -618M -47.3M -46.28M -1.99B -17.2M -15.3M -14.28M -13.04M -24.46M -1.66B -24.82M -172M -66.89M -844M -64.57M -63.17M -2.72B
Net Debt - -
Logo Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Employees
-
Date Price Change Volume
01/10/26 US$0.9700 -10.19% 109,145
30/09/26 US$1.080 -0.92% 21,796
29/09/26 US$1.090 -2.68% 38,760
28/09/26 US$1.120 -2.61% 75,647
25/09/26 US$1.150 -4.17% 224,862
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.080USD
Average target price
14.00USD
Spread / Average Target
+1,196.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CVKD Stock